An article authored by Boyds’ Chief Development Officer, Dr Nick Meyers, and Director of Regulatory Affairs, Dr Eric Hardter, has published in the Sep-Oct 2025 issue of European Pharmaceutical Manufacturer.
In the article, Nick and Eric provide advice and guidance to drug developers and sponsors on de-risking the IND process.
For those operating in the US market, a clear understanding of the FDA’s expectations and the product-specific complexities of its Investigational New Drug (IND) application process is crucial to best prevent an adverse regulatory response.
The piece can be viewed on pp56-57 of the magazine here and online here.